Paper41329461
CRISPR/Cas9 Genome Editing in Oncology: Mechanisms, Therapeutic Platforms and Translational Challenges.
Nguyen AH and 1 other. Mol Biotechnol, 2026. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. CRISPR/Cas9 Genome Editing in Oncology: Mechanisms, Therapeutic Platforms and Translational Challenges. Papers, record 41329461. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41329461
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CRISPR/Cas9 Genome Editing in Oncology: Mechanisms, Therapeutic Platforms and Translational Challenges.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| CRISPR-Cas Systems | Major topic |
| Neoplasms | Major topic |
| Gene Editing | Major topic |
| Humans | |
| Animals | |
| Genetic Therapy | |
| Translational Research, Biomedical |
Source PubMed
References207
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31745080 | Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. | Nat Commun | 2019 | https://conductscience.org/library/papers/31745080 | PubMed |
| 2 | 34963897 | Ultrasound-Controlled CRISPR/Cas9 System Augments Sonodynamic Therapy of Hepatocellular Carcinoma. | ACS Cent Sci | 2021 | https://conductscience.org/library/papers/34963897 | PubMed |
| 3 | 30666307 | Engineering and Design of Chimeric Antigen Receptors. | Mol Ther Methods Clin Dev | 2019 | https://conductscience.org/library/papers/30666307 | PubMed |
| 4 | 36969176 | Experimental mouse models for translational human cancer research. | Front Immunol | 2023 | https://conductscience.org/library/papers/36969176 | PubMed |
| 5 | 38734692 | Enhancing genome editing in hPSCs through dual inhibition of DNA damage response and repair pathways. | Nat Commun | 2024 | https://conductscience.org/library/papers/38734692 | PubMed |
| 6 | 40983440 | The role and regulation of cell death in cancer. | Prog Mol Biol Transl Sci | 2025 | https://conductscience.org/library/papers/40983440 | PubMed |
| 7 | 28807568 | Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. | Mol Ther | 2017 | https://conductscience.org/library/papers/28807568 | PubMed |
| 8 | 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385370 | PubMed |
| 9 | 21941284 | A decade of exploring the cancer epigenome - biological and translational implications. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21941284 | PubMed |
| 10 | 38260716 | Recent Advancements in Reducing the Off-Target Effect of CRISPR-Cas9 Genome Editing. | Biologics | 2024 | https://conductscience.org/library/papers/38260716 | PubMed |
| 11 | 39349459 | CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. | Nat Commun | 2024 | https://conductscience.org/library/papers/39349459 | PubMed |
| 12 | 26771115 | The Emerging Hallmarks of Cancer Metabolism. | Cell Metab | 2016 | https://conductscience.org/library/papers/26771115 | PubMed |
| 13 | 26735016 | High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. | Nature | 2016 | https://conductscience.org/library/papers/26735016 | PubMed |
| 14 | 25730490 | Highly efficient Cas9-mediated transcriptional programming. | Nat Methods | 2015 | https://conductscience.org/library/papers/25730490 | PubMed |
| 15 | 38467308 | Orthotopic and metastatic tumour models in preclinical cancer research. | Pharmacol Ther | 2024 | https://conductscience.org/library/papers/38467308 | PubMed |
| 16 | 27096365 | Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. | Nature | 2016 | https://conductscience.org/library/papers/27096365 | PubMed |
| 17 | 37429857 | Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9. | Nat Commun | 2023 | https://conductscience.org/library/papers/37429857 | PubMed |
| 18 | 35952360 | Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. | Cancer Res | 2022 | https://conductscience.org/library/papers/35952360 | PubMed |
| 19 | 36894722 | Sniper2L is a high-fidelity Cas9 variant with high activity. | Nat Chem Biol | 2023 | https://conductscience.org/library/papers/36894722 | PubMed |
| 20 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42771321 | Electroporation for High-Efficiency Delivery of CRISPR to Hematopoietic Cells. | Methods Mol Biol | 2027 | https://conductscience.org/library/papers/42771321 | PubMed |
| 42649936 | Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649936 | PubMed |
| 42601370 | Design and transfection of CRISPR/Cas9 constructs for the myostatin gene in Labeo rohita muscle cells. | Sci Rep | 2026 | https://conductscience.org/library/papers/42601370 | PubMed |
| 42211656 | CRISPR-driven strategies to disrupt methicillin-resistant Staphylococcus aureus biofilms: a review. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42211656 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41329461
GET https://conductscience.org/api/papers/v1/41329461/references?page=2